scholarly journals Reliability of Diagnostic Tests forHelicobacter pyloriInfection

2011 ◽  
Vol 2011 ◽  
pp. 1-6 ◽  
Author(s):  
S. Redéen ◽  
F. Petersson ◽  
E. Törnkrantz ◽  
H. Levander ◽  
E. Mårdh ◽  
...  
Keyword(s):  
Histological Examination ◽  
Gold Standard ◽  
Diagnostic Tests ◽  
Breath Test ◽  
Eradication Therapy ◽  
Urea Breath Test ◽  
Rapid Urease Test ◽  
First Choice ◽  
Urease Test ◽  
H Pylori

Introduction.Helicobacter pylori (H. pylori)infection is very common worldwide. A reliable diagnosis is crucial for patients withH. pylori-related diseases. At followup, it is important to confirm that eradication therapy has been successful. There is no established gold standard for the diagnosis ofH. pyloriinfection.Material and Methods. A sample of 304 volunteers from the general population was screened forH. pyloriinfection with serology,13C-urea breath test (UBT), rapid urease test (RUT) on fresh biopsy, culture from biopsy, and histological examination. Culture was used as gold standard.Results. The sensitivity was 0.99 for serology, 0.90 for UBT, 0.90 for RUT, and 0.90 for histological examination. Corresponding specificities were 0.82, 0.99, 0.98, and 0.97, respectively. The accuracy was 0.86 for serology, 0.96 for UBT, 0.95 for RUT, 0.93 for culture, and 0.95 for histology. There was a strong correlation between the results of UBT and the histological scores ofH. pyloricolonisation as well as between the results of UBT and the scores of RUT.Conclusion. There were only minor differences in accuracy between the three invasive tests forH. pyloriinfection in this population. RUT may be recommended as the first choice since a result is obtained within hours. The accuracy of UBT was comparable to the invasive tests, and it is recommended for situations when endoscopy is not needed.

scholarly journals Clinical Validation of an Office-Based14C-UBT (Heliprobe) forH. pyloriDiagnosis in Iranian Dyspeptic Patients

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Fariborz Mansour-Ghanaei ◽  
Omid Sanaei ◽  
Farahnaz Joukar
Keyword(s):  
Predictive Value ◽  
Gold Standard ◽  
Urea Breath Test ◽  
Diagnostic Methods ◽  
Rapid Urease Test ◽  
Clinical Validation ◽  
Igg Antibodies ◽  
Urease Test ◽  
Gastric Biopsies ◽  
H Pylori

Background. We encountered repeatedly, in our clinical practice, discordant results between UBT and histopathology aboutH. pyloriinfection.Goal. To study the diagnostic accuracy of Heliprobe14C-urea breath test (14C-UBT) for detection ofH. pyloriinfection in an Iranian population.Study. We enrolled 125 dyspeptic patients in our study. All of them underwent gastroscopy, and four gastric biopsies (three from the antrum and one from the corpus) were obtained. One of the antral biopsies was utilized for a rapid urease test (RUT), and three others were evaluated under microscopic examination. Sera from all patients were investigated for the presence ofH. pyloriIgG antibodies. The14C-UBT was performed on all subjects using Heliprobe kit, and results were analyzed against the following gold standard (GS):H. pyloriinfection considered positive when any two of three diagnostic methods (histopathology, RUT, serology) are positive.Results. According to data analysis, the Heliprobe14C-UBT had 94% sensitivity, 100% specificity, 93% negative predictive value (NPV), 100% positive predictive value (PPV), and 97% accuracy, compared with GS.Conclusion. The Heliprobe14C-UBT is an easy-to-perform, rapid-response, and accurate test forH. pyloridiagnosis, suitable for office use.

scholarly journals Low Prevalence ofHelicobacter PyloriInfection in Canadian Children: A Cross-Sectional Analysis

2008 ◽  
Vol 22 (5) ◽  
pp. 485-489 ◽  
Author(s):  
Idit Segal ◽  
Anthony Otley ◽  
Robert Issenman ◽  
David Armstrong ◽  
Victor Espinosa ◽  
...  
Keyword(s):  
Sensitivity And Specificity ◽  
Breath Test ◽  
Tertiary Care ◽  
Urea Breath Test ◽  
Rapid Urease Test ◽  
Infection Rates ◽  
Upper Gi ◽  
Gi Symptoms ◽  
Urease Test ◽  
H Pylori

BACKGROUND: The incidence and prevalence rates of childhoodHelicobacter pyloriinfection vary greatly by nation, with infection rates of 8.9% to 72.8% reported in developed and developing countries, respectively. To date, few studies have assessed the prevalence ofH pyloriin Canadian children, with studies limited to Aboriginal communities and single tertiary care centres from Ontario and Quebec.OBJECTIVES: To determine the prevalence ofH pyloriin consecutive children referred to three Canadian tertiary care academic centres for upper gastrointestinal (GI) endoscopy due to upper GI symptoms, and to determine the sensitivity and specificity of the carbon-13-labelled urea breath test, the rapid urease test and theH pyloristool monoclonal antigen test.RESULTS: Two hundred four patients were recruited. The prevalence ofH pyloriwas 7.1%. Of theH pylori-positive patients, 41.7% were male, with a mean age of 10.3 years. Ethnic minorities accounted for 42% of theH pylori-positive patients. Consistent with previous observations, the sensitivity and specificity of the carbon-13-labelled urea breath test were 1.0 and 0.98, respectively. The sensitivity and specificity of the rapid urease test were 1.0 and 0.99, respectively. Stool samples were collected from 34 patients from one centre, with a sensitivity and specificity of 1.0 and 0.68, respectively. No defining symptoms ofH pyloriinfection were evident and no peptic ulcer disease was demonstrated.CONCLUSION:H pyloriinfection rates in Canadian children with upper GI symptoms are low, and are lower than those reported for other developed countries. Further studies are required in Canada to determine the prevalence in the general population and specifically in the populations at risk.

scholarly journals The validity of breath collection bags method in detecting Helicobacter pylori using the novel BreathID®Hp Lab System: a multicenter clinical study in 257 subjects

2019 ◽  
Vol 12 ◽  
pp. 263177451984340 ◽  
Author(s):  
Vered Richter ◽  
Jeff O. Gonzalez ◽  
Sabine Hazan ◽  
Gary Gottlieb ◽  
Keith Friedenberg ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Clinical Study ◽  
Breath Test ◽  
Therapy Group ◽  
Eradication Therapy ◽  
Test System ◽  
Urea Breath Test ◽  
Rapid Urease Test ◽  
Test Results ◽  
Urease Test

Background and Aim: The BreathID® Hp urea breath test provides several advantages over other 13C breath analyzers for the detection of Helicobacter pylori. We evaluated the sensitivity and specificity of a new BreathID® Hp Lab System (Exalenz Bioscience Ltd, Israel), a 13C-urea breath test system using breath sampling bags that facilitates multiple testing in a multicenter international clinical study. Methods: A total of 257 subjects with evaluable results for urea breath test, rapid urease test, and histology were enrolled into two study groups: 189 naïve subjects were included in the pre-therapy group, and 68 subjects comprised the post-eradication therapy group. Analytical studies were conducted to evaluate the stability, reproducibility, and repeatability of the 13C-urea breath test results using a delta over baseline cut-off value of 5. Results: Among the pre-therapy subjects evaluated with the composite results from the rapid urease test and histology/immunohistochemistry, 176 results matched those of the urea breath test, resulting in an overall agreement of 98.3% with a sensitivity of 100% and specificity of 97.9%. In the post-eradication therapy cohort, the overall agreement between the urea breath test and the biopsy diagnosis was 98.5%; the sensitivity of the urea breath test in this cohort was 92.3% and the specificity was 100%. There was uniformly high overall reproducibility (99.48%) of the test results over different batches of breath sample bags, when analyzed on different days and under different storage conditions, showing stability of the breath samples in the breath collection bags Conclusion: The BreathID® Hp Lab System is a highly accurate and dependable method for the diagnosis of H. pylori infection.

The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori-Positive Chronic Thrombocytopenic Purpura.

Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 4002-4002 ◽  
Author(s):  
Seung-Hyun Nam ◽  
Bong-Seog Kim ◽  
Jae Hoon Lee ◽  
Hong Suk Song ◽  
Sung-Hwa Bae ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Platelet Count ◽  
Breath Test ◽  
Urea Breath Test ◽  
Rapid Urease Test ◽  
Thrombocytopenic Purpura ◽  
Platelet Recovery ◽  
Chronic Itp ◽  
Urease Test ◽  
H Pylori

Abstract Background: Helicobacter pylori (H pylori) has been implicated in the pathogenesis of some autoimmune diseases including idiopathic thrombocytopenic purpura (ITP). Several studies recently showed a high prevalence of H pylori infection in patients with ITP and reported a platelet recovery after bacterial eradication therapy. The prevalence of H pylori infection and effect of its eradication in Korea patients with chronic ITP were investigated. Methods: The study included among 35 patients with chronic ITP from eight hospitals. H pylori infection was assessed by urea breath test, rapid urease test or microbial culture. H pylori eradication was performed with amoxicillin, clarithromycin and omeprazol regimen for 7 days or bismuth, metronidazol and tetracycline regimen for 10 days. Eradication was assessed by urea breath test 4 weeks after treatment. Platelet counts were monitored serially after the end of treatment. Results: Thirty five patients with chronic ITP were evaluated, including 12 males and 23 females. Median age was 57 years (range 30–79). The median platelet count before eradication was 23,000/uL (range 4,000–66,000/uL). Sixteen patients were performed the splenectomy previously. H pylori infection was found in 23 (65%) of 35 patients. In 21 patients performed the eradication, 6 patients (28.5%) had a significant increase in platelet count after 2 weeks and 2 months. The response duration was 1–27 (median 7.6) months. Conclusions: This study confirmed the efficacy of H pylori eradication in increasing platelet in adult chronic ITP patients. We must consider the investigation and eradication of H pylori infection in ITP patients as a simple, inexpensive tool in management of the chronic disease.

scholarly journals Eradication of Helicobacter pylori in patients without gastric symptoms suffering from recurrent aphthous stomatitis: A pilot study

2017 ◽  
Vol 74 (7) ◽  
pp. 672-675 ◽  
Author(s):  
Marina Latkovic ◽  
Lazar Ranin ◽  
Nevenka Teodorovic ◽  
Marko Andjelkovic
Keyword(s):  
Eradication Therapy ◽  
Recurrent Aphthous Stomatitis ◽  
Aphthous Stomatitis ◽  
Diffusion Method ◽  
Gastric Disease ◽  
Warning Sign ◽  
Rapid Urease Test ◽  
Sensitivity Testing ◽  
Urease Test ◽  
H Pylori

Background/Aim. Helicobacter (H.) pylori is a widespread bacterium and its involvement in pathogenesis of gastric diseases is well-known. However, H. pylori role in etiology of other histologically similar conditions, especially recurrent aphthous stomatitis (RAS) is still controversial. Research regarding H. pylori and its association with RAS, as well as the treatment options were always conducted on patients with diagnosed gastric problems. The aim of this study was to determine whether H. pylori is present in the oral cavity of patients suffering from RAS but without any symptoms or medical history of gastric disease. Methods. A total of 15 patients with RAS participated in the study. None of the participants suffered from any gastrointestinal disorders. Two dental plaque samples from each participant were collected. The first was analyzed using rapid urease test and the second one was put in transport medium and sent for cultivation. The sensitivity of H. pylori to antibiotics was established using disk diffusion method of sensitivity testing for every patient individually and adequate therapy was prescribed. Results. Before the treatment the mean annual recurrence rate of RAS was 8.1 ? 2.1, with the average number of lesions being 3.9 ? 1.9. During the 12-month observation period after the eradication therapy, none of the patients reported recurrence of aphthous lesions. The treatment was successful in all cases. Conclusion. This study shows that RAS can be effectively treated by successful eradication of oral H. pylori, and that RAS could be possibly considered as an early warning sign of potential gastric infection by H. pilory.

scholarly journals Can probiotics improve efficiency and safety profile of triple Helicobacter pylori eradication therapy? A prospective randomized study

2016 ◽  
Vol 73 (11) ◽  
pp. 1044-1049 ◽  
Author(s):  
Sasa Grgov ◽  
Tomislav Tasic ◽  
Biljana Radovanovic-Dinic ◽  
Daniela Benedeto-Stojanov
Keyword(s):  
Helicobacter Pylori ◽  
Randomized Study ◽  
Eradication Therapy ◽  
Saccharomyces Boulardii ◽  
Rapid Urease Test ◽  
Group I ◽  
Urease Test ◽  
Probiotic Strains ◽  
The Difference ◽  
H Pylori

Background/Aim. Some studies suggest the benefit of applying different probiotic strains in combination with antibiotics in the eradication of Helicobacter pylori (H. pylori) infection. The aim of this study was to evaluate the effect of co-administration of multiple probiotic strains with triple H. pylori eradication therapy. Methods. This prospective study included 167 patients with dyspeptic symptoms and chronic gastritis who were diagnosed with H. pylori infection and randomized into two groups. The group I of 77 patients underwent triple eradication therapy, for 7 days, with lansoprazole, 2 ? 30 mg half an hour before the meal, amoxicillin 2 ? 1.000 mg per 12 hours and clarithromycin 2 ? 500 mg per 12 hours. After the 7th day of the therapy, lansoprazole continued at a dose of 30 mg for half an hour before breakfast for 4 weeks. The group II of 90 patients received the same treatment as the patients of the group I, with the addition of the probiotic cultures in the form of a capsule comprising Lactobacillus Rosell-52, Lactobacillus Rosell-11, Bifidobacterium Rosell-1755 and Saccharomyces boulardii, since the beginning of eradication for 4 weeks. Eradication of H. pylori infection control was performed 8 weeks after the therapy by rapid urease test and histopathologic evaluation of endoscopic biopsies or by stool antigen test for H. pylori. Results. Eradication of H. pylori infection was achieved in 93.3% of the patients who received probiotics with eradication therapy and in 81.8% of patients who were only on eradication therapy without probiotics. The difference in eradication success was statistically significant, (p < 0.05). The incidence of adverse effects of eradication therapy was higher in the group of patients who were not on probiotic (28.6%) than in the group that received probiotic (17.7%), but the difference was not statistically significant. Conclusion. Multiple probiotic strains addition to triple eradication therapy of H. pylori achieves a significantly better eradication success, with fewer side effects of antibiotics.

Helicobacter pylori causes gastrointestinal hemorrhage in patients with congenital bleeding disorders

2003 ◽  
Vol 89 (04) ◽  
pp. 741-746 ◽  
Author(s):  
Ann-Sofie Rehnberg ◽  
Marju Hein ◽  
Olga Hegedus ◽  
Per Lindmarker ◽  
Per Hellström ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gastrointestinal Hemorrhage ◽  
Breath Test ◽  
Eradication Therapy ◽  
Urea Breath Test ◽  
Von Willebrand Disease ◽  
Bleeding Disorders ◽  
Ulcer Disease ◽  
H Pylori ◽  
One Year

Summary Helicobacter pylori (H. pylori) infection is associated with peptic ulcer disease and gastric cancer. The eradication of H. pylori is of special interest in patients with congenital bleeding disorders, for whom treatment of gastrointestinal hemorrhage with factor concentrates is costly. The prevalence of H. pylori varies between different populations and identification of high-risk subgroups may allow for more targeted screening and eradication of the infection. We performed a 5-year retrospective study of gastrointestinal bleeding, combined with screening and treatment for H. pylori and a long-term prospective follow-up in 168 Swedish and 23 Estonian patients with hemophilia or von Willebrand disease. The prevalence of seropositivity was lower in Sweden than in Estonia (28 versus 48%, p = 0.03), lower in native Swedes than in non-Nordic immigrants to Sweden (20 versus 76%, p = 0.0001) and lower in patients less than 40 years of age than older patients (16 versus 38%, p = 0.002). The incidence of gastrointestinal hemorrhages among the 35 Swedish patients with active H. pylori infection, confirmed by a urea breath test, was 6.0 per 100 patient-years before eradication therapy versus 1.7 during the prospective followup. A negative urea breath test one month after therapy always remained negative after one year. Screening, followed by treatment of all infected patients, yielded a reduction of direct costs over a 5-year period of 130 US-$ per screened patient. We conclude that screening and eradication therapy for infection with H. pylori in patients with congenital bleeding disorders is an effective and economic strategy.

Good diagnostic accuracy of a chemiluminescent immunoassay in stool samples for diagnosis of Helicobacter pylori infection in patients with dyspepsia

2016 ◽  
Vol 64 (2) ◽  
pp. 388-391 ◽  
Author(s):  
María José Ramírez-Lázaro ◽  
Josep Lite ◽  
Sergio Lario ◽  
Pepa Pérez-Jové ◽  
Antònia Montserrat ◽  
...  
Keyword(s):  
Helicobacter Pylori ◽  
Gold Standard ◽  
Rapid Urease Test ◽  
Diagnostic Reliability ◽  
Predictive Values ◽  
Urease Test ◽  
Stool Samples ◽  
H Pylori ◽  
Good Diagnostic Accuracy ◽  
Sensitivity Specificity

Laboratory-based chemiluminescence immunoassays (CLIA) are widely used in clinical laboratories. Some years ago, a CLIA test was developed for the detection of Helicobacter pylori in stool samples, known as LIAISON H. pylori SA, but little information on its use has been reported. To evaluate the accuracy of the LIAISON H. pylori SA assay for diagnosing H. pylori infection prior to eradication treatment. Diagnostic reliability was evaluated in 252 untreated consecutive patients with dyspepsia. The gold standard for diagnosing H. pylori infection was defined as the concordance of the rapid urease test (RUT), histopathology and urea breath test (UBT). The CLIA assay was performed according to the manufacturer's instructions. Sensitivity, specificity, positive and negative predictive values, and 95% CIs were calculated. According to the gold standard selected, 121 patients were positive for H. pylori infection and 131 negative. LIAISON H. pylori SA had a sensitivity of 90.1% and a specificity of 92.4%, with positive and negative predictive values of 91.6% and 90.1%, respectively. The accuracy of the LIAISON H. pylori SA chemiluminescent diagnostic assay seems comparable to that of ELISA or the best-performing LFIAs. Its sensitivity and specificity, however, seem slightly lower than those of histology, RUT or UBT. The advantages of the assay are that it is cheap, automated, and minimally labor-intensive.

Sign in / Sign up

Export Citation Format

Share Document